Pharma multinationals have started off strong in China in the first quarter, helped by growth for both mature and newer products, but several are also issuing cautions that there may be a general slowing in growth amid broader changes in the economy. A new competitive bidding scheme in major cities in particular is expected to put considerable further pricing pressures on some companies and products.
Pointing to a historical high growth rate in emerging markets in the first quarter, AstraZeneca PLC said this was being driven by China, which soared by
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?